<html>
<head>
<META http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>NCT00144300 on 2006_01_24: ClinicalTrials.gov Archive</title>
<link rel="stylesheet" href="/archive/history.css">
<link rel="stylesheet" href="/archive/received.css">
</head>
<body class="received">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="navLinks" class="navLinks"><a href="/archive/NCT00144300">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00144300">&#8593; Current version of this study</a></div><h1>View of NCT00144300 on
  2006_01_24</h1>
<table class="info">
<tr>
<th nowrap>ClinicalTrials Identifier:</th><td>NCT00144300</td>
</tr>
<tr>
<th>Updated:</th><td>2006_01_24</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Descriptive Information</h2>
</th>
</tr>
<tr>
<th>Brief title</th><td>
<p>A Two-Year Open-Label, Randomized, Parallel Group Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients</p>
</td>
</tr>
<tr>
<th>Official title</th><td>
<p>A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients</p>
</td>
</tr>
<tr>
<th>Brief summary</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>To determine if there is any difference in the presence of retinal deterioration in PD patients treated with pramipexole IR versus ropinirole as monitored by comprehensive ophthalmologic assessments from baseline to the end of study at two years.</p>
</td>
</tr>
<tr>
<th>Detailed description</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p></p>
</td>
</tr>
<tr>
<th>Phase</th><td>Phase 4</td>
</tr>
<tr>
<th>Study type</th><td>Interventional</td>
</tr>
<tr>
<th>Study design</th><td>Treatment</td>
</tr>
<tr>
<th>Study design</th><td>Randomized</td>
</tr>
<tr>
<th>Study design</th><td>Open Label</td>
</tr>
<tr>
<th>Study design</th><td>Active Control</td>
</tr>
<tr>
<th>Study design</th><td>Parallel Assignment</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: 
         To determine if there is any difference in the presence of retinal deterioration in Parkinson's disease patients treated with pramipexole versus ropinirole.
      </td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: 
         To assess and monitor safety and tolerability of pramipexole versus ropinirole in Parkinson's disease patients; to assess progression of Parkinson's disease over the study period.
      </td>
</tr>
<tr>
<th>Condition</th><td>
         Parkinson Disease
      </td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: pramipexole</div>
</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Recruitment Information</h2>
</th>
</tr>
<tr>
<th>Status</th><td>
            Recruiting
         </td>
</tr>
<tr>
<th>Start date</th><td>
         2005-01
      </td>
</tr>
<tr>
<th>End date</th><td>
         2009-10
      </td>
</tr>
<tr>
<th>Criteria</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>Diagnosis and main criteria for inclusion: &nbsp;&nbsp;Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study (all time periods are calculated from randomization.):<br>1. Patients with idiopathic Parkinson's disease for at least 2 years confirmed by at least two of the following signs: resting tremor, bradykinesia, rigidity; and characterized as Stage I-III by the Modified Hoehn and Yahr Scale.<br>2. On stable dosage of levodopa for at least 4 weeks.<br>3. Age between 30 and 80 years old<br>4. Women of childbearing potential must have a negative serum beta-HCG pregnancy test at the Screen (Baseline) visit and the patient must use adequate contraceptive methods.<br>5. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.<br>6. Patients who are willing and able to comply with scheduled visits, treatment plan, and other study procedures.<br>7. HAMD total score of greater than 15.<br>8. Mini-Mental &nbsp;State Examination (MMSE) score greater than 23.</p>
</td>
</tr>
<tr>
<th>Gender</th><td>
            Both
         </td>
</tr>
<tr>
<th>Minimum age</th><td>30 Years</td>
</tr>
<tr>
<th>Maximum age</th><td>80 Years</td>
</tr>
<tr>
<th>Healthy volunteers</th><td>No</td>
</tr>
<tr>
<th>Expected enrollment</th><td>300</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Administrative Data</h2>
</th>
</tr>
<tr>
<th>Organization name</th><td>Boehringer Ingelheim Pharmaceuticals</td>
</tr>
<tr>
<th>Organization study ID</th><td>248.538</td>
</tr>
<tr>
<th>Sponsor</th><td>
               Boehringer Ingelheim Pharmaceuticals
            </td>
</tr>
<tr>
<th>Health Authority</th><td>
               United States: Food and Drug Administration
         </td>
</tr>
</table><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div></body>
</html>
